tiprankstipranks
Capstone Therapeutics Corp (CAPS)
OTHER OTC:CAPS
US Market

Capstone Therapeutics (CAPS) Stock Price & Analysis

15 Followers

CAPS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$4.90 - $37.00
Previous Close$5.35
Volume9.00
Average Volume (3M)N/A
Market Cap
$290.96K
Enterprise Value$54.23M
Total Cash (Recent Filing)$23.00K
Total Debt (Recent Filing)$28.80M
Price to Earnings (P/E)-0.2
Beta0.11
Aug 15, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-31.27
Shares Outstanding54,385,411
10 Day Avg. Volume1
30 Day Avg. VolumeN/A
Standard Deviation0.26
R-Squared0.02
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-18.68
Price to Sales (P/S)-141.40
Price to Cash Flow (P/CF)29.10
P/FCF Ratio16.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.88
Enterprise Value/Gross Profit3.28
Enterprise Value/Ebitda12.81
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

CAPS FAQ

What was Capstone Therapeutics Corp’s price range in the past 12 months?
Capstone Therapeutics Corp lowest stock price was $4.90 and its highest was $37.00 in the past 12 months.
    What is Capstone Therapeutics Corp’s market cap?
    Currently, no data Available
    When is Capstone Therapeutics Corp’s upcoming earnings report date?
    Capstone Therapeutics Corp’s upcoming earnings report date is Aug 15, 2023 which is 248 days ago.
      How were Capstone Therapeutics Corp’s earnings last quarter?
      Capstone Therapeutics Corp released its earnings results on May 12, 2023. The company reported -$12.512 earnings per share for the quarter, missing the consensus estimate of N/A by -$12.512.
        Is Capstone Therapeutics Corp overvalued?
        According to Wall Street analysts Capstone Therapeutics Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Capstone Therapeutics Corp pay dividends?
          Capstone Therapeutics Corp does not currently pay dividends.
          What is Capstone Therapeutics Corp’s EPS estimate?
          Capstone Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Capstone Therapeutics Corp have?
          Capstone Therapeutics Corp has 54,385 shares outstanding.
            What happened to Capstone Therapeutics Corp’s price movement after its last earnings report?
            Capstone Therapeutics Corp reported an EPS of -$12.512 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Capstone Therapeutics Corp?
              Currently, no hedge funds are holding shares in CAPS
              ---

              Capstone Therapeutics Stock Smart Score

              Company Description

              Capstone Therapeutics Corp

              Capstone Therapeutics Corp. is a biotechnology company. It develops a pipeline of novel therapeutic peptides and other molecules aimed at helping patients with under-served medical conditions. The company was founded in July 1987 and is headquartered in Tempe, AZ.
              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              Bio-Path Holdings
              Gyre Therapeutics
              Protalix
              Capricor Therapeutics
              Popular Stocks
              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis